Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.phrs.2020.104916 http://scihub22266oqcxt.onion/10.1016/j.phrs.2020.104916 32445957!7238995!32445957     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pharmacol+Res 2020 ; 159 (ä): 104916 Nephropedia Template TP {{tp|p=32445957|t=2020. Clinical approach to the inflammatory etiology of cardiovascular diseases |pdf=|usr=}}{{32445957}} gab.com Text Clinical approach to the inflammatory etiology of cardiovascular diseases JO: Pharmacol Res http://www.kidney.de/pget.php?&tw=1&pmid=32445957 #FOAvip Inflammation is an obligatory marker of arterial disease, both stemming from the inflammatory activity of cholesterol itself and from well-established molecular mechanisms. Raised progenitor cell recruitment after major events and clonal hematopoiesis related mechanisms have provided an improved understanding of factors regulating inflammatory phenomena. Trials with inflammation antagonists have led to an extensive evaluation of biomarkers such as the high sensitivity C reactive protein (hsCRP), not exerting a causative role, but frequently indicative of the individual cardiovascular (CV) risk. Aim of this review is to provide indication on the anti-inflammatory profile of agents of general use in CV prevention, i.e. affecting lipids, blood pressure, diabetes as well nutraceuticals such as n-3 fatty acids. A crucial issue in the evaluation of the benefit of the anti-inflammatory activity is the frequent discordance between a beneficial activity on a major risk factor and associated changes of hsCRP, as in the case of statins vs PCSK9 antagonists. In hypertension, angiotensin converting enzyme inhibitors exert an optimal anti-inflammatory activity, vs the case of sartans. The remarkable preventive activity of SLGT-2 inhibitors in heart failure is not associated with a clear anti-inflammatory mechanism. Finally, icosapent ethyl has been shown to reduce the CV risk in hypertriglyceridemia, with a 27 % reduction of hsCRP. The inflammation-based approach to arterial disease has considerably gained from an improved understanding of the clinical diagnostic strategy and from a better knowledge on the mode of action of numerous agents, including nutraceuticals. Twit Text FOAVip Clinical approach to the inflammatory etiology of cardiovascular diseases ????Pharmacol Res http://www.kidney.de/pget.php?&tw=1&pmid=32445957 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32445957 #FOAvip English Wikipedia <ref>{{Cite pmid|32445957}}</ref> Clinical approach to the inflammatory etiology of cardiovascular diseases #MMPMID32445957 Ruscica M; Corsini A; Ferri N; Banach M; Sirtori CR Pharmacol Res 2020[Sep]; 159 (ä): 104916 PMID32445957show ga Inflammation is an obligatory marker of arterial disease, both stemming from the inflammatory activity of cholesterol itself and from well-established molecular mechanisms. Raised progenitor cell recruitment after major events and clonal hematopoiesis related mechanisms have provided an improved understanding of factors regulating inflammatory phenomena. Trials with inflammation antagonists have led to an extensive evaluation of biomarkers such as the high sensitivity C reactive protein (hsCRP), not exerting a causative role, but frequently indicative of the individual cardiovascular (CV) risk. Aim of this review is to provide indication on the anti-inflammatory profile of agents of general use in CV prevention, i.e. affecting lipids, blood pressure, diabetes as well nutraceuticals such as n-3 fatty acids. A crucial issue in the evaluation of the benefit of the anti-inflammatory activity is the frequent discordance between a beneficial activity on a major risk factor and associated changes of hsCRP, as in the case of statins vs PCSK9 antagonists. In hypertension, angiotensin converting enzyme inhibitors exert an optimal anti-inflammatory activity, vs the case of sartans. The remarkable preventive activity of SLGT-2 inhibitors in heart failure is not associated with a clear anti-inflammatory mechanism. Finally, icosapent ethyl has been shown to reduce the CV risk in hypertriglyceridemia, with a 27 % reduction of hsCRP. The inflammation-based approach to arterial disease has considerably gained from an improved understanding of the clinical diagnostic strategy and from a better knowledge on the mode of action of numerous agents, including nutraceuticals. |Animals[MESH] |Anti-Inflammatory Agents/*therapeutic use[MESH] |Antihypertensive Agents/therapeutic use[MESH] |Cardiovascular Agents/*therapeutic use[MESH] |Cardiovascular Diseases/etiology/metabolism/physiopathology/*prevention & control[MESH] |Cardiovascular System/*drug effects/metabolism/physiopathology[MESH] |Diabetes Mellitus/drug therapy/metabolism/physiopathology[MESH] |Dietary Supplements[MESH] |Dyslipidemias/drug therapy/metabolism/physiopathology[MESH] |Gastrointestinal Microbiome[MESH] |Heart Disease Risk Factors[MESH] |Humans[MESH] |Hypertension/drug therapy/metabolism/physiopathology[MESH] |Hypoglycemic Agents/therapeutic use[MESH] |Hypolipidemic Agents/therapeutic use[MESH] |Inflammation Mediators/*antagonists & inhibitors/metabolism[MESH] |Inflammation/*drug therapy/etiology/metabolism/physiopathology[MESH] |Risk Assessment[MESH]Clinical approach to the inflammatory etiology of cardiovascular disea(epmc).pdf DeepDyve Pubget Overpricing